Figure 3
From: Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Disease control vs. progressive disease. Kaplan-Meier analyses of time to progression (a) and survival since initiating TKI therapy (b) in months among patients that had a response or stable disease (solid line) and patients that had progressive disease (dashed line).
